Latest California Healthline Stories
A Free-for-All From Readers and Tweeters, From Medical Debt to Homelessness
KHN gives readers a chance to comment on a recent batch of stories.
As Big Pharma Loses Interest in New Antibiotics, Infections Are Only Growing Stronger
Existing drugs still treat most infections. But that has discouraged investment in new drugs that will be needed when — not if —the old ones fail.
KHN’s ‘What the Health?’: Life After ‘Roe’ Is … Confusing
A rapidly changing landscape for abortion has left patients, providers, employers, and lawmakers alike wondering what is and is not legal and what to do next. Meanwhile, Democrats in Congress have resumed negotiations on legislation to lower drug prices and, potentially, continue expanded insurance subsidies for the Affordable Care Act. Alice Miranda Ollstein of Politico, Tami Luhby of CNN, and Sandhya Raman of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.
Patients With Epilepsy Navigate Murky Unregulated CBD Industry
The FDA has approved a cannabis-derived drug, Epidiolex, to treat some forms of epilepsy. Now people who have other forms of the condition are using over-the-counter CBD products in hopes of taming their seizures. But doctors and patients worry about the unregulated world of CBD, in which product ingredients can be a mystery.
‘Free’ Screening? Know Your Rights to Get No-Cost Care
Even a decade in, the Affordable Care Act’s recommendations to simply cover preventive screening and care without cost sharing remain confusing and complex.
How Pfizer Won the Pandemic, Reaping Outsize Profit and Influence
The drugmaker has the best-selling vaccine to prevent covid and the most effective drug to treat it. Its success has overshadowed the government’s covid-fighting strategy.
Cómo Pfizer le ganó a la pandemia, alcanzando influencia y ganancias descomunales
Su éxito en el desarrollo de medicamentos contra covid le ha dado a la farmacéutica un peso inusual en la determinación de la política de salud de Estados Unidos. Algo que preocupa a expertos.
Readers and Tweeters Weigh In on Medical Debt, the Obesity Epidemic, and Opioid Battles
KHN gives readers a chance to comment on a recent batch of stories.
KHN’s ‘What the Health?’: The FDA Goes After Nicotine
The FDA is using its power to regulate tobacco products — ordering the vaping device Juul off the market and announcing its intention to lower the amount of nicotine in cigarettes and other products. Meanwhile, the Supreme Court rules on Medicare and kidney dialysis, and Congress makes progress on legislation surrounding guns and mental health. Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, and Rachel Cohrs of Stat join KHN’s Julie Rovner to discuss these issues and more. Also this week, Rovner interviews KHN’s Noam N. Levey about the new KHN-NPR project on the growing impact of medical debt.
New Weight Loss Treatment Is Marked by Heavy Marketing and Modest Results
Approved as a device, not a drug, Plenity contains a plant-based gel that swells to fill 25% of a person’s stomach, to help people eat less. Results vary widely but are modest on average.